156 related articles for article (PubMed ID: 22878783)
1. Understanding how breast cancer patients use risk information from genomic tests.
DeFrank JT; Carey LA; Brewer NT
J Behav Med; 2013 Dec; 36(6):567-73. PubMed ID: 22878783
[TBL] [Abstract][Full Text] [Related]
2. When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.
Brewer NT; Edwards AS; O'Neill SC; Tzeng JP; Carey LA; Rimer BK
Breast Cancer Res Treat; 2009 Sep; 117(1):25-9. PubMed ID: 18785002
[TBL] [Abstract][Full Text] [Related]
3. Health literacy and cancer risk perception: implications for genomic risk communication.
Brewer NT; Tzeng JP; Lillie SE; Edwards AS; Peppercorn JM; Rimer BK
Med Decis Making; 2009; 29(2):157-66. PubMed ID: 19050227
[TBL] [Abstract][Full Text] [Related]
4. Association between genomic recurrence risk and well-being among breast cancer patients.
Retèl VP; Groothuis-Oudshoorn CG; Aaronson NK; Brewer NT; Rutgers EJ; van Harten WH
BMC Cancer; 2013 Jun; 13():295. PubMed ID: 23777535
[TBL] [Abstract][Full Text] [Related]
5. Knowledge of genomic testing among early-stage breast cancer patients.
Richman AR; Tzeng JP; Carey LA; Retèl VP; Brewer NT
Psychooncology; 2011 Jan; 20(1):28-35. PubMed ID: 20200857
[TBL] [Abstract][Full Text] [Related]
6. Women's experiences with genomic testing for breast cancer recurrence risk.
Tzeng JP; Mayer D; Richman AR; Lipkus I; Han PK; Valle CG; Carey LA; Brewer NT
Cancer; 2010 Apr; 116(8):1992-2000. PubMed ID: 20213682
[TBL] [Abstract][Full Text] [Related]
7. Knowledge about genomic recurrence risk testing among breast cancer survivors.
Lipkus IM; Vadaparampil ST; Jacobsen PB; Miree CA
J Cancer Educ; 2011 Dec; 26(4):664-9. PubMed ID: 21688183
[TBL] [Abstract][Full Text] [Related]
8. Improving communication of breast cancer recurrence risk.
Brewer NT; Richman AR; DeFrank JT; Reyna VF; Carey LA
Breast Cancer Res Treat; 2012 Jun; 133(2):553-61. PubMed ID: 21964579
[TBL] [Abstract][Full Text] [Related]
9. Who gets genomic testing for breast cancer recurrence risk?
DeFrank JT; Salz T; Reeder-Hayes K; Brewer NT
Public Health Genomics; 2013; 16(5):215-22. PubMed ID: 23899493
[TBL] [Abstract][Full Text] [Related]
10. Women's interest in gene expression analysis for breast cancer recurrence risk.
O'Neill SC; Brewer NT; Lillie SE; Morrill EF; Dees EC; Carey LA; Rimer BK
J Clin Oncol; 2007 Oct; 25(29):4628-34. PubMed ID: 17925559
[TBL] [Abstract][Full Text] [Related]
11. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
Kittaneh M; Badve S; Caldera H; Coleman R; Goetz MP; Mahtani R; Mamounas E; Kalinsky K; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Traina T; Vogel C
Clin Breast Cancer; 2020 Jun; 20(3):183-193. PubMed ID: 32014370
[TBL] [Abstract][Full Text] [Related]
12. Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
Evans CN; Brewer NT; Vadaparampil ST; Boisvert M; Ottaviano Y; Lee MC; Isaacs C; Schwartz MD; O'Neill SC
Breast Cancer Res Treat; 2016 Apr; 156(3):549-555. PubMed ID: 27059031
[TBL] [Abstract][Full Text] [Related]
13. Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy.
Lillie SE; Brewer NT; O'Neill SC; Morrill EF; Dees EC; Carey LA; Rimer BK
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):249-55. PubMed ID: 17267389
[TBL] [Abstract][Full Text] [Related]
14. How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
Marshall DA; Deal K; Bombard Y; Leighl N; MacDonald KV; Trudeau M
BMJ Open; 2016 Jun; 6(6):e010981. PubMed ID: 27256091
[TBL] [Abstract][Full Text] [Related]
15. Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
Spellman E; Sulayman N; Eggly S; Peshkin BN; Isaacs C; Schwartz MD; O'Neill SC
Psychooncology; 2013 Sep; 22(9):2110-6. PubMed ID: 23447452
[TBL] [Abstract][Full Text] [Related]
16. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
[TBL] [Abstract][Full Text] [Related]
17. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
[TBL] [Abstract][Full Text] [Related]
18. Saudi women's interest in breast cancer gene testing: possible influence of awareness, perceived risk and socio-demographic factors.
Amin TT; Al-Wadaani HA; Al-Quaimi MM; Aldairi NA; Alkhateeb JM; Al-Jaafari AA
Asian Pac J Cancer Prev; 2012; 13(8):3879-87. PubMed ID: 23098487
[TBL] [Abstract][Full Text] [Related]
19. Preferences for learning different types of genome sequencing results among young breast cancer patients: Role of psychological and clinical factors.
Kaphingst KA; Ivanovich J; Lyons S; Biesecker B; Dresser R; Elrick A; Matsen C; Goodman M
Transl Behav Med; 2018 Jan; 8(1):71-79. PubMed ID: 29385583
[TBL] [Abstract][Full Text] [Related]
20. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
Gage MM; Mylander WC; Rosman M; Fujii T; Le Du F; Raghavendra A; Sinha AK; Espinosa Fernandez JR; James A; Ueno NT; Tafra L; Jackson RS
Ann Oncol; 2018 May; 29(5):1280-1285. PubMed ID: 29788166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
